These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 16942925

  • 1. Urinary gamma-glutamyltransferase (GGT) as a potential marker of bone resorption.
    Asaba Y, Hiramatsu K, Matsui Y, Harada A, Nimura Y, Katagiri N, Kobayashi T, Takewaka T, Ito M, Niida S, Ikeda K.
    Bone; 2006 Dec; 39(6):1276-82. PubMed ID: 16942925
    [Abstract] [Full Text] [Related]

  • 2. Urinary bone resorption markers (deoxypyridinoline and C-terminal telopeptide of type I collagen) in healthy persons, postmenopausal osteoporosis and patients with type I diabetes.
    Fassbender WJ, Gödde M, Brandenburg VM, Usadel KH, Stumpf UC.
    Adv Med Sci; 2009 Dec; 54(1):1-6. PubMed ID: 19482729
    [Abstract] [Full Text] [Related]

  • 3. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
    DeLaurier A, Jackson B, Pfeiffer D, Ingham K, Horton MA, Price JS.
    Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950
    [Abstract] [Full Text] [Related]

  • 4. Markers of bone resorption--measurement in serum, plasma or urine?
    Huber F, Traber L, Roth HJ, Heckel V, Schmidt-Gayk H.
    Clin Lab; 2003 Aug; 49(5-6):203-7. PubMed ID: 15285175
    [Abstract] [Full Text] [Related]

  • 5. Analytical and clinical evaluation of the Bio-Rad HPLC kit for measurement of type I collagen cross links.
    Srivastava AK, Libanati C, Oberrauch W, Leenings J, Greenwald M, Baylink DJ.
    J Bone Miner Metab; 2003 Aug; 21(3):134-44. PubMed ID: 12720047
    [Abstract] [Full Text] [Related]

  • 6. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis.
    Seibel MJ, Cosman F, Shen V, Gordon S, Dempster DW, Ratcliffe A, Lindsay R.
    J Bone Miner Res; 1993 Jul; 8(7):881-9. PubMed ID: 8352070
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Bone and bone related biochemical examinations. Bone and collagen related metabolites. DPD (total, free)].
    Takada J, Imoto K, Iba K, Yamashita T.
    Clin Calcium; 2006 Jun; 16(6):994-1000. PubMed ID: 16751696
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W.
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ, Im JA, Kim SH.
    Maturitas; 2008 Jun 20; 60(2):170-6. PubMed ID: 18572334
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
    Okabe R, Inaba M, Nakatsuka K, Miki T, Naka H, Moriguchi A, Nishizawa Y.
    J Bone Miner Metab; 2004 Jun 20; 22(2):127-31. PubMed ID: 14999523
    [Abstract] [Full Text] [Related]

  • 18. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis.
    Torikai E, Kageyama Y, Takahashi M, Suzuki M, Ichikawa T, Nagafusa T, Nagano A.
    Rheumatology (Oxford); 2006 Jun 20; 45(6):761-4. PubMed ID: 16436492
    [Abstract] [Full Text] [Related]

  • 19. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
    Kitatani K, Nakatsuka K, Naka H, Miki T, Morii H, Nishizawa Y.
    J Bone Miner Metab; 2003 Jun 20; 21(4):217-24. PubMed ID: 12811626
    [Abstract] [Full Text] [Related]

  • 20. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis.
    Delmas PD, Schlemmer A, Gineyts E, Riis B, Christiansen C.
    J Bone Miner Res; 1991 Jun 20; 6(6):639-44. PubMed ID: 1887826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.